FCF margin is calculated as Free Cash Flow divided by its Revenue. VistaGen Therapeutics's Free Cash Flow for the
three
months ended in Dec. 2021 was $-12.05 Mil. VistaGen Therapeutics's Revenue for the
three
months ended in Dec. 2021 was $0.36 Mil. Therefore, VistaGen Therapeutics's FCF margin for the quarter that ended in Dec. 2021 was -3,364.80%.
VistaGen Therapeutics FCF Margin % Historical Data
The historical data trend for VistaGen Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
FCF Margin %
-600.08
-
-
-
-1,132.94
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
FCF Margin %
-1,588.85
-1,195.02
-1,786.16
-3,212.57
-3,364.80
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics FCF Margin % Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's FCF Margin % falls into.
VistaGen Therapeutics FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
VistaGen Therapeutics's FCF Margin for the fiscal year that ended in Mar. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics FCF Margin % Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.06(5.41%) Volume: 1,357,426 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
